Thompson Siegel & Walmsley’s AstraZeneca AZN Stock Holding History

Thompson Siegel & Walmsley’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$408K	Hold	2,152	–	–	0.01%	380
2026 Q1	$424K	Sell	2,152 -10	-0.5%	-$1.93K	0.01%	368
2025 Q4	$398K	Hold	2,162	–	–	0.01%	358
2025 Q3	$332K	Hold	2,162	–	–	0.01%	373
2025 Q2	$302K	Hold	2,162	–	–	0.01%	370
2025 Q1	$318K	Buy	2,162 +96	+5%	+$13.9K	0.01%	354
2024 Q4	$271K	Hold	2,066	–	–	﹤0.01%	360
2024 Q3	$322K	Hold	2,066	–	–	﹤0.01%	349
2024 Q2	$322K	Hold	2,066	–	–	0.01%	328
2024 Q1	$280K	Sell	2,066 -252	-11%	-$33.4K	﹤0.01%	336
2023 Q4	$312K	Sell	2,318 -312	-12%	-$40.6K	0.01%	320
2023 Q3	$356K	Sell	2,630 -45	-2%	-$6.15K	0.01%	307
2023 Q2	$383K	Sell	2,675 -53	-2%	-$7.8K	0.01%	319
2023 Q1	$379K	Sell	2,728 -24	-0.9%	-$3.23K	0.01%	310
2022 Q4	$373K	Hold	2,752	–	–	0.01%	306
2022 Q3	$302K	Sell	2,752 -143	-5%	-$18.1K	0.01%	318
2022 Q2	$382K	Sell	2,895 -3,750	-56%	-$492K	0.01%	301
2022 Q1	$882K	Sell	6,645 -667	-9%	-$80K	0.01%	275
2021 Q4	$852K	Sell	7,312 -767	-9%	-$90.2K	0.01%	278
2021 Q3	$970K	Buy	8,079 +7,795	+2,745%	+$907K	0.01%	269
2021 Q2	$34K	Hold	284	–	–	﹤0.01%	537
2021 Q1	$28K	Sell	284 -180	-39%	-$18.1K	﹤0.01%	532
2020 Q4	$46K	Hold	464	–	–	﹤0.01%	456
2020 Q3	$51K	Sell	464 -100	-18%	-$11.1K	﹤0.01%	423
2020 Q2	$60K	Hold	564	–	–	﹤0.01%	414
2020 Q1	$50K	Hold	564	–	–	﹤0.01%	402
2019 Q4	$56K	Hold	564	–	–	﹤0.01%	476
2019 Q3	$50K	Hold	564	–	–	﹤0.01%	501
2019 Q2	$47K	Sell	564 -116	-17%	-$9.1K	﹤0.01%	513
2019 Q1	$55K	Hold	680	–	–	﹤0.01%	494
2018 Q4	$52K	Hold	680	–	–	﹤0.01%	484
2018 Q3	$54K	Hold	680	–	–	﹤0.01%	514
2018 Q2	$48K	Hold	680	–	–	﹤0.01%	532
2018 Q1	$48K	Hold	680	–	–	﹤0.01%	524
2017 Q4	$47K	Hold	680	–	–	﹤0.01%	543
2017 Q3	$46K	Sell	680 -2,770	-80%	-$175K	﹤0.01%	525
2017 Q2	$235K	Sell	3,450 -3,156	-48%	-$206K	﹤0.01%	415
2017 Q1	$411K	Buy	6,606 +401	+6%	+$23.3K	﹤0.01%	408
2016 Q4	$339K	Sell	6,205 -3,775	-38%	-$214K	﹤0.01%	380
2016 Q3	$656K	Sell	9,980 -413	-4%	-$27K	0.01%	322
2016 Q2	$627K	Sell	10,393 -1,187	-10%	-$68.9K	0.01%	308
2016 Q1	$652K	Sell	11,580 -3,275	-22%	-$197K	0.01%	301
2015 Q4	$1.01M	Sell	14,855 -1,300	-8%	-$85.2K	0.02%	277
2015 Q3	$1.03M	Sell	16,155 -1,750	-10%	-$115K	0.02%	279
2015 Q2	$1.14M	Buy	17,905 +1,430	+9%	+$97.9K	0.02%	273
2015 Q1	$1.13M	Buy	16,475 +45	+0.3%	+$3.13K	0.02%	266
2014 Q4	$1.16M	Buy	16,430 +1,000	+6%	+$71.6K	0.02%	271
2014 Q3	$1.1M	Hold	15,430	–	–	0.02%	270
2014 Q2	$1.15M	Buy	15,430 +1,525	+11%	+$110K	0.02%	271
2014 Q1	$902K	Buy	13,905 +3,900	+39%	+$252K	0.02%	286
2013 Q4	$594K	Hold	10,005	–	–	0.01%	309
2013 Q3	$520K	Hold	10,005	–	–	0.01%	321
2013 Q2	$473K	Buy	+10,005	New	+$509K	0.01%	333

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Thompson Siegel & Walmsley's AZN Position: Q2 2026 in Review

Thompson Siegel & Walmsley held its AstraZeneca (AZN) position steady in Q2 2026 at 2,152 shares worth $408K. The position accounts for 0.01% of the portfolio, ranked #380.

Thompson Siegel & Walmsley first reported a position in AZN in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.16M in Q4 2014. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Thompson Siegel & Walmsley held 2,152 shares of AstraZeneca worth $408K as of Q2 2026.
Thompson Siegel & Walmsley left its AstraZeneca share count unchanged in Q2 2026.
AstraZeneca made up 0.01% of Thompson Siegel & Walmsley's portfolio in Q2 2026, its #380 holding.
Thompson Siegel & Walmsley first reported a position in AstraZeneca in Q2 2013 and has held it in 53 quarters since.
Thompson Siegel & Walmsley's AstraZeneca position peaked at $1.16M in Q4 2014.
1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Thompson Siegel & Walmsley's 13F filing for Q2 2026, filed 11 Aug 2026.